Abstract
Following chemotherapy, secondary acute myeloid leukemia (sAML), occurring after antecedent hematologic diseases, previous chemotherapy or radiation, has an inferior prognosis compared with de novo AML. To define the outcome of sAML in the context of allogeneic stem cell transplantation (alloSCT), a retrospective, registry-based comparison was performed, including 11,439 patients with de novo and 1325 with sAML. Among transplants in first complete remission (CR1) (n = 8,600), the 3-year cumulative incidence of relapse (RI) and non-relapse mortality (NRM) was 28.5% and 16.4% for de novo, and 35% and 23.4% for sAML. Three-year overall survival (OS), leukemia-free survival (LFS) and Graft-versus-Host Disease/relapse-free survival (GRFS) was 60.8%, 55.1%, and 38.6% for de novo, and 46.7%, 41.6%, and 28.4% for sAML, respectively. In multivariate analysis, sAML was associated with a lower OS (HR = 1.33 [95% CI = 1.21-1.48]; p < 10-5), LFS (HR = 1.32 [95% CI = 1.19-1.45]; p < 10-5) and GRFS (HR = 1.2 [95% CI = 1.1-1.31]; p < 10-4) and higher NRM (HR = 1.37 [95% CI = 1.17-1.59]; p < 10-4) and RI (HR = 1.27 [95% CI = 1.12-1.44]; p < 10-3). Results of the Cox model were confirmed in a matched-pair analysis. In contrast, results did not d...Continue Reading
References
Oct 31, 2003·Leukemia·C SchochT Haferlach
Feb 4, 2006·Blood·Frederick R AppelbaumStephen H Petersdorf
Aug 21, 2007·Current Oncology Reports·Gautam Borthakur, And Elihu E Estey
Dec 25, 2007·Blood·Vinod PullarkatFrederick R Appelbaum
Aug 12, 2008·Seminars in Oncology·Lucy A Godley, Richard A Larson
May 15, 2009·Cancer·Gautam BorthakurHagop Kantarjian
May 20, 2009·Cancer·David A RizzieriJoseph O Moore
May 5, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Boglarka GyurkoczaBrenda M Sandmaier
Dec 4, 2010·Blood·Sabine KayserUNKNOWN German-Austrian AMLSG
Feb 9, 2011·Blood·Elias CampoElaine S Jaffe
Nov 7, 2012·Bone Marrow Transplantation·S-H ShinY-J Kim
Jun 4, 2014·Leukemia·R B WalterB M Sandmaier
Nov 26, 2014·American Journal of Hematology·Erik HulegårdhSören Lehmann
Jan 17, 2015·Blood·Shernan G HoltanDaniel J Weisdorf
Mar 31, 2015·Bone Marrow Transplantation·F V MichelisH A Messner
Aug 26, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Lene Sofie Granfeldt ØstgårdJan Maxwell Nørgaard
Nov 16, 2016·Haematologica·Shannon R McCurdyLeo Luznik
Nov 30, 2016·Blood·Hartmut DöhnerClara D Bloomfield
Jan 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Marie BalsatNicolas Boissel
Mar 21, 2017·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Bartlomiej M GettaMikhail Roshal
Apr 8, 2017·Cancer·Prajwal Chaitanya BodduTapan M Kadia
Mar 15, 2018·American Journal of Hematology·Zhuoyan LiArnon Nagler
Apr 22, 2018·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·Salyka SengsayadethArnon Nagler
Jul 20, 2018·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeffrey E LancetBruno C Medeiros
Aug 6, 2018·Annals of Hematology·Esther SchulerUlrich Germing
Aug 26, 2018·Blood Advances·Salyka SengsayadethArnon Nagler
Jan 1, 2019·American Journal of Hematology·Catherine J LeeArnon Nagler
Citations
Oct 3, 2020·Blood Advances·Vikas GuptaWael Saber
Nov 26, 2020·Annals of Hematology·Yue LuDao-Pei Lu
Nov 20, 2020·Bone Marrow Transplantation·Madlen JentzschSebastian Schwind
Mar 30, 2021·Leukemia & Lymphoma·Daniela V WengeMatthias Stelljes
Jun 2, 2021·Bone Marrow Transplantation·Johanna WaidhauserUNKNOWN Acute Leukemia Working Party of EBMT
Aug 6, 2021·Leukemia & Lymphoma·Masamitsu YanadaShingo Yano
Jul 22, 2021·American Journal of Hematology·Juliane GrimmSebastian Schwind
Aug 25, 2021·Transplantation and Cellular Therapy·Leland MethenyMarcos de Lima
Sep 18, 2021·Current Opinion in Hematology·Anne E Austin, Michael Byrne